Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 12, 2014, Pages 2121-2130.e2

  Vuppalanchi, Raj ^a   Jain, Ajay K ^b   Deppe, Ross ^a   Yates, Katherine ^c   Comerford, Megan ^a   Masuoka, Howard C ^a   Neuschwander Tetri, Brent A ^b   Loomba, Rohit ^d   Brunt, Elizabeth M ^f   Kleiner, David E ^g   Molleston, Jean P ^a   Schwimmer, Jeffrey B ^e,h   Lavine, Joel E ⁱ   Tonascia, James ^c   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h RADY CHILDREN'S HOSPITAL   (United States)

ⁱ Howard Hughes Medical Institute   (United States)

Author keywords

Nonalcoholic Steatohepatitis; Noninvasive Biomarker; PIVENS; Serum K18; TONIC

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; CYTOKERATIN 18; METFORMIN; PIOGLITAZONE; PLACEBO; KRT18 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CHILD; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; BIOPSY; BLOOD; CHEMISTRY; CYTOCHEMISTRY; LIVER; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SERUM;

ADOLESCENT; ADULT; BIOPSY; CHILD; HISTOCYTOCHEMISTRY; HUMANS; KERATIN-18; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERUM;

EID: 84918770626     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.05.010     Document Type: Article

References (31)

1. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
2. Bellentani S., Scaglioni F., Marino M., et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010, 28:155-161.
3. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
4. Gupta R., Bhangoo A., Matthews N.A., et al. The prevalence of non-alcoholic fatty liver disease and metabolic syndrome in obese children. JPediatr Endocrinol Metab 2011, 24:907-911.
5. Szczepaniak L.S., Nurenberg P., Leonard D., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005, 288:E462-E468.
6. Farrell G.C., Wong V.W., Chitturi S. NAFLD in Asia-as common and important as in the West. Nat Rev Gastroenterol Hepatol 2013, 10:307-318.
7. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012, 107:811-826.
8. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
9. Ascha M.S., Hanouneh I.A., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
10. Neuschwander-Tetri B.A., Clark J.M., Bass N.M., et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010, 52:913-924.
11. Sanyal A.J., Brunt E.M., Kleiner D.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54:344-353.
12. Canbay A., Friedman S., Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39:273-278.
13. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
14. Canbay A., Feldstein A.E., Higuchi H., et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003, 38:1188-1198.
15. Moll R., Divo M., Langbein L. The human keratins: biology and pathology. Histochem Cell Biol 2008, 129:705-733.
16. Feldstein A.E., Alkhouri N., De Vito R., et al. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 2013, 108:1526-1531.
17. Yilmaz Y., Dolar E., Ulukaya E., et al. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med Sci Monit 2009, 15:CR189-CR193.
18. Tsutsui M., Tanaka N., Kawakubo M., et al. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. JClin Gastroenterol 2010, 44:440-447.
19. Shen J., Chan H.L., Wong G.L., et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. JHepatol 2012, 56:1363-1370.
20. Feldstein A.E., Wieckowska A., Lopez A.R., et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078.
21. Musso G., Gambino R., Cassader M., et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011, 43:617-649.
22. Cusi K., Chang Z., Harrison S., et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. JHepatol 2014, 60:167-174.
23. Chalasani N.P., Sanyal A.J., Kowdley K.V., et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009, 30:88-96.
24. Lavine J.E., Schwimmer J.B., Molleston J.P., et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010, 31:62-70.
25. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. NEngl J Med 2010, 362:1675-1685.
26. Lavine J.E., Schwimmer J.B., Van Natta M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
27. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
28. Cui J. Estimating AIDS incidence and jack-knife variance from a continuous delay distribution and incomplete data. Stat Med 1999, 18:527-537.
29. Chen J., Zhu Y., Zheng Q., et al. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: a meta-analysis. Hepatol Res 2013 Jul 9, Epub ahead of print.
30. Kwok R., Tse Y.K., Wong G.L., et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease - the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014, 39:254-269.
31. Peviva. M30 apoptosense ELISA, REF 10010. Instructions for use. Bromma, Sweeden: 2010; p.12.